Literature DB >> 10673305

Automated measurement of unsaturated iron binding capacity is an effective screening strategy for C282Y homozygous haemochromatosis.

P E Hickman1, L F Hourigan, L W Powell, F Cordingley, G Dimeski, B Ormiston, J Shaw, W Ferguson, M Johnson, J Ascough, K McDonell, A Pink, D H Crawford.   

Abstract

BACKGROUND: C282Y hereditary haemochromatosis is an appropriate condition for population screening. Transferrin saturation, the best screening test to date, is relatively expensive, labour intensive, and cannot be automated. Unsaturated iron binding capacity is a surrogate marker of transferrin saturation and its measurement can be automated. AIMS: To evaluate a screening strategy for C282Y hereditary haemochromatosis in a tertiary hospital environment based on unsaturated iron binding capacity as the initial screening test.
METHODS: Measurement of unsaturated iron binding capacity was adapted to the main laboratory analyser. An unsaturated iron binding capacity of less than 30 micromol/l was identified as an appropriate decision point and 5182 consecutive subjects were screened over 28 consecutive days.
RESULTS: Of those screened, 697 had an unsaturated iron binding capacity less than 30 micromol/l. Of these, transferrin saturation was greater than 40% in 294. A total of 227 were able to be genotyped for the C282Y mutation. Nine subjects homozygous for C282Y were identified. Based on full cost recovery, affected persons were identified at a cost of Aus$2268.77 per case (approximately US$1496).
CONCLUSION: Automated measurement of unsaturated iron binding capacity enables a cost effective, large scale population screening programme for C282Y hereditary haemochromatosis to be developed.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10673305      PMCID: PMC1727865          DOI: 10.1136/gut.46.3.405

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  20 in total

1.  A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis.

Authors:  J N Feder; A Gnirke; W Thomas; Z Tsuchihashi; D A Ruddy; A Basava; F Dormishian; R Domingo; M C Ellis; A Fullan; L M Hinton; N L Jones; B E Kimmel; G S Kronmal; P Lauer; V K Lee; D B Loeb; F A Mapa; E McClelland; N C Meyer; G A Mintier; N Moeller; T Moore; E Morikang; C E Prass; L Quintana; S M Starnes; R C Schatzman; K J Brunke; D T Drayna; N J Risch; B R Bacon; R K Wolff
Journal:  Nat Genet       Date:  1996-08       Impact factor: 38.330

2.  Haemochromatosis and HLA-H.

Authors:  E C Jazwinska; L M Cullen; F Busfield; W R Pyper; S I Webb; L W Powell; C P Morris; T P Walsh
Journal:  Nat Genet       Date:  1996-11       Impact factor: 38.330

3.  Haemochromatosis and HLA-H.

Authors:  A M Jouanolle; G Gandon; P Jézéquel; M Blayau; M L Campion; J Yaouanq; J Mosser; P Fergelot; B Chauvel; P Bouric; G Carn; N Andrieux; I Gicquel; J Y Le Gall; V David
Journal:  Nat Genet       Date:  1996-11       Impact factor: 38.330

4.  Prevalence of haemochromatosis amongst asymptomatic Australians.

Authors:  B A Leggett; J W Halliday; N N Brown; S Bryant; L W Powell
Journal:  Br J Haematol       Date:  1990-04       Impact factor: 6.998

5.  Screening for hemochromatosis.

Authors:  M L Bassett; J W Halliday; S Bryant; O Dent; L W Powell
Journal:  Ann N Y Acad Sci       Date:  1988       Impact factor: 5.691

6.  A screening test for assessing iron status.

Authors:  J Pintar; B S Skikne; J D Cook
Journal:  Blood       Date:  1982-01       Impact factor: 22.113

Review 7.  Practice guideline development task force of the College of American Pathologists. Hereditary hemochromatosis.

Authors:  D L Witte; W H Crosby; C Q Edwards; V F Fairbanks; F A Mitros
Journal:  Clin Chim Acta       Date:  1996-02-28       Impact factor: 3.786

8.  Screening test for iron overload.

Authors:  B S Skikne; J D Cook
Journal:  Am J Clin Nutr       Date:  1987-11       Impact factor: 7.045

Review 9.  Clinical characteristics of hereditary hemochromatosis patients who lack the C282Y mutation.

Authors:  N J Shaheen; B R Bacon; I S Grimm
Journal:  Hepatology       Date:  1998-08       Impact factor: 17.425

10.  Long-term survival in patients with hereditary hemochromatosis.

Authors:  C Niederau; R Fischer; A Pürschel; W Stremmel; D Häussinger; G Strohmeyer
Journal:  Gastroenterology       Date:  1996-04       Impact factor: 22.682

View more
  3 in total

Review 1.  How to identify the genetic basis of gastrointestinal and liver diseases?

Authors:  P Ferenci
Journal:  Gut       Date:  2003-05       Impact factor: 23.059

Review 2.  Hemochromatosis. Common genes, uncommon illness?

Authors:  Helen Harrison; Paul C Adams
Journal:  Can Fam Physician       Date:  2002-08       Impact factor: 3.275

Review 3.  Screening for hemochromatosis: patients with liver disease, families, and populations.

Authors:  Sumedha P Galhenage; Charlie H Viiala; John K Olynyk
Journal:  Curr Gastroenterol Rep       Date:  2004-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.